Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.65 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.65 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ADH1B | P00325 | 1/20 | 0.47 |
| ▸ | ADH1C | P00326 | 1/20 | 0.47 |
| ▸ | ADH1A | P07327 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8520812 | 0.98 | SPHK2 (0.63) | SPHK2SPHK1SCN3AMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL7760565 | 0.89 | SPHK2 (0.56) | SPHK2SPHK1SCN3AALDH1A1DPP7 | |
| SCHEMBL8843444 | 0.89 | SPHK2 (0.58) | SPHK2SPHK1SCN3AMEN1KMT2A | |
| Carbamic Acid SCHEMBL15635796 | 0.85 | HDAC8 (0.60) | MEN1KMT2ATDP1HDAC8HDAC6 | |
| SCHEMBL7391510 | 0.84 | SPHK2 (0.82) | SPHK2SPHK1SCN3A | |
| SCHEMBL9334106 | 0.83 | GAA (0.56) | SPHK2SPHK1MEN1KMT2AALDH1A1 | |
| SCHEMBL156664 | 0.83 | MEN1 (0.56) | MEN1KMT2ATDP1HDAC8HDAC6 | |
| SCHEMBL5181873 | 0.83 | THRB (0.56) | SPHK2SPHK1MEN1KMT2ATDP1 | |
| SCHEMBL11273783 | 0.82 | CA2 (0.55) | SPHK2SPHK1SCN3A | |
| Ammonia Solution, Strong SCHEMBL27486735 | 0.81 | MEN1 (0.54) | MEN1KMT2ATDP1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535310-B1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | COCA COLA CO (US) | 2025-12-24 | — | — | EP | claimed |
| US-11708454-B2 | Acrolein scavenging in PTF and other 1,3-propanediol derived polymers | THE COCA-COLA COMPANY (US) | 2023-07-25 | — | — | US | claimed |
| US-20190330420-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | THE COCA-COLA COMPANY (US) | 2019-10-31 | — | — | US | claimed |
| EP-3535310-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | The Coca-Cola Company (US) | 2019-09-11 | — | — | EP | claimed |
| CN-109996830-A | Acrolein scavenger in PTF and other 1, 3-propanediol derived polymers | 可口可乐公司 | 2019-07-09 | — | — | CN | claimed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| CN-101497613-A | Preparation of praziquanamine | FUYANG GENEBEST CHEMICAL INDUS (CN) | 2009-08-05 | — | — | CN | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| EP-1606283-B1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2008100727-A2 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-0230151-A2 | Cholecystokinin antagonists | BIOMEASURE, INC. (US) | 1987-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | SPHK2 1595/4885SPHK1 2212/4885SCN3A 3888/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | SPHK2 124/4885SPHK1 144/4885SCN3A 2698/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | SPHK2 3568/4885SPHK1 3676/4885SCN3A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.